• 15416 Citations
  • 52 Scopus h-Index
1978 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
2020

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

Ramanathan, R. K., Von Hoff, D. D., Eskens, F., Blumenschein, G., Richards, D., Genvresse, I., Reschke, S., Granvil, C., Skubala, A., Peña, C. & Mross, K., Apr 1 2020, In : Targeted Oncology. 15, 2, p. 163-174 12 p.

Research output: Contribution to journalArticle

Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors

Strickler, J. H., LoRusso, P., Salgia, R., Kang, Y. K., Yen, C. J., Lin, C. C., Ansell, P., Motwani, M., Wong, S., Yue, H., Wang, L., Reilly, E., Afar, D., Naumovski, L. & Ramanathan, R. K., May 1 2020, In : Molecular cancer therapeutics. 19, 5, p. 1210-1217 8 p.

Research output: Contribution to journalArticle

Open Access

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

Mahalingam, D., Patel, M. R., Sachdev, J. C., Hart, L. L., Halama, N., Ramanathan, R. K., Sarantopoulos, J., Völkel, D., Youssef, A., de Jong, F. A. & Tsimberidou, A. M., Jan 1 2020, (Accepted/In press) In : British Journal of Clinical Pharmacology.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations
2019

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

Gorbunova, V., Beck, J. T., Hofheinz, R. D., Garcia-Alfonso, P., Nechaeva, M., Cubillo Gracian, A., Mangel, L., Elez Fernandez, E., Deming, D. A., Ramanathan, R. K., Torres, A. H., Sullivan, D., Luo, Y. & Berlin, J. D., Jan 22 2019, In : British journal of cancer. 120, 2, p. 183-189 7 p.

Research output: Contribution to journalArticle

4 Scopus citations

A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer

Ramanathan, R. K., Thomas, G. W., Khorana, A. A., Shah, S., Zhou, C., Wong, S., Cole, G., James, D. & Gabrail, N. Y., Apr 1 2019, In : Oncology (Switzerland). 96, 4, p. 217-222 6 p.

Research output: Contribution to journalArticle

Open Access
4 Scopus citations

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial

Shroff, R. T., Javle, M. M., Xiao, L., Kaseb, A. O., Varadhachary, G. R., Wolff, R. A., Raghav, K. P. S., Iwasaki, M., Masci, P., Ramanathan, R. K., Ahn, D. H., Bekaii-Saab, T. S. & Borad, M. J., Jun 2019, In : JAMA Oncology. 5, 6, p. 824-830 7 p.

Research output: Contribution to journalArticle

24 Scopus citations

Hepatocytes direct the formation of a pro-metastatic niche in the liver

Lee, J. W., Stone, M. L., Porrett, P. M., Thomas, S. K., Komar, C. A., Li, J. H., Delman, D., Graham, K., Gladney, W. L., Hua, X., Black, T. A., Chien, A. L., Majmundar, K. S., Thompson, J. C., Yee, S. S., O’Hara, M. H., Aggarwal, C., Xin, D., Shaked, A., Gao, M. & 9 others, Liu, D., Borad, M. J., Ramanathan, R. K., Carpenter, E. L., Ji, A., de Beer, M. C., de Beer, F. C., Webb, N. R. & Beatty, G. L., Mar 14 2019, In : Nature. 567, 7747, p. 249-252 4 p.

Research output: Contribution to journalArticle

39 Scopus citations

Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

De Jesus-Acosta, A., Sugar, E. A., O’Dwyer, P. J., Ramanathan, R. K., Von Hoff, D. D., Rasheed, Z., Zheng, L., Begum, A., Anders, R., Maitra, A., McAllister, F., Rajeshkumar, N. V., Yabuuchi, S., de Wilde, R. F., Batukbhai, B., Sahin, I. & Laheru, D. A., Jan 1 2019, (Accepted/In press) In : British journal of cancer.

Research output: Contribution to journalArticle

2 Scopus citations

Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313

Ramanathan, R. K., McDonough, S. L., Philip, P. A., Hingorani, S. R., Lacy, J., Kortmansky, J. S., Thumar, J., Chiorean, E. G., Shields, A. F., Behl, D., Mehan, P. T., Gaur, R., Seery, T., Guthrie, K. A. & Hochster, H. S., Jan 1 2019, In : Journal of Clinical Oncology. 37, 13, p. 1062-1069 8 p.

Research output: Contribution to journalArticle

29 Scopus citations

Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment among Patients with Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial

Jameson, G. S., Borazanci, E., Babiker, H. M., Poplin, E., Niewiarowska, A. A., Gordon, M. S., Barrett, M. T., Rosenthal, A., Stoll-D'astice, A., Crowley, J., Shemanski, L., Korn, R. L., Ansaldo, K., Lebron, L., Ramanathan, R. K. & Von Hoff, D. D., Jan 1 2019, (Accepted/In press) In : JAMA Oncology.

Research output: Contribution to journalArticle

3 Scopus citations
2018

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

Berlin, J., Ramanathan, R. K., Strickler, J. H., Subramaniam, D. S., Marshall, J., Kang, Y. K., Hetman, R., Dudley, M. W., Zeng, J., Nickner, C., Xiong, H., Komarnitsky, P., Shepherd, S. P., Hurwitz, H. & Lenz, H. J., Mar 12 2018, (Accepted/In press) In : British Journal of Cancer. p. 1-9 9 p.

Research output: Contribution to journalArticle

4 Scopus citations

A phase II clinical investigation of BPM31510-IV (ubidecarenone) in patients with advanced pancreatic cancer

Niewiarowska, A. A., Lucius, D. M., Sarangarajan, R., Narain, N. R., Ramanathan, R., Ritch, P., Strauss, J., Kundranda, M. & Propper, D., Oct 1 2018, In : Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. viii270

Research output: Contribution to journalArticle

Open Access

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Moschos, S. J., Sullivan, R. J., Hwu, W. J., Ramanathan, R. K., Adjei, A. A., Fong, P. C., Shapira-Frommer, R., Tawbi, H. A., Rubino, J., Rush, T. S., Zhang, D., Miselis, N. R., Samatar, A. A., Chun, P., Rubin, E. H., Schiller, J., Long, B. J., Dayananth, P., Carr, D., Kirschmeier, P. & 8 others, Bishop, W. R., Deng, Y., Cooper, A., Shipps, G. W., Moreno, B. H., Robert, L., Ribas, A. & Flaherty, K. T., Feb 22 2018, In : JCI Insight. 3, 4

Research output: Contribution to journalArticle

Open Access
31 Scopus citations

First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody–drug conjugate targeting c-Met, in patients with advanced solid tumors

Strickler, J. H., Weekes, C. D., Nemunaitis, J., Ramanathan, R. K., Heist, R. S., Morgensztern, D., Angevin, E., Bauer, T. M., Yue, H., Motwani, M., Parikh, A., Reilly, E. B., Afar, D., Naumovski, L. & Kelly, K., Nov 20 2018, In : Journal of Clinical Oncology. 36, 33, p. 3298-3306 9 p.

Research output: Contribution to journalArticle

11 Scopus citations

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

Infante, J. R., Korn, R. L., Rosen, L. S., Lorusso, P., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G., Von Hoff, D. D., Borad, M. J. & Ramanathan, R. K., Jan 1 2018, In : British journal of cancer. 118, 2, p. 153-161 9 p.

Research output: Contribution to journalArticle

25 Scopus citations

Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma

Javle, M., Lowery, M., Shroff, R. T., Weiss, K. H., Springfeld, C., Borad, M. J., Ramanathan, R. K., Goyal, L., Sadeghi, S., Macarulla, T., El-Khoueiry, A., Kelley, R. K., Borbath, I., Choo, S. P., Oh, D. Y., Philip, P. A., Chen, L. T., Reungwetwattana, T., Van Cutsem, E., Yeh, K. H. & 9 others, Ciombor, K., Finn, R. S., Patel, A., Sen, S., Porter, D., Isaacs, R., Zhu, A. X., Abou-Alfa, G. K. & Bekaii-Saab, T., Jan 20 2018, In : Journal of Clinical Oncology. 36, 3, p. 276-282 7 p.

Research output: Contribution to journalArticle

127 Scopus citations

Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors

Lam, E. T., Eckhardt, S. G., Messersmith, W., Jimeno, A., O'Bryant, C. L., Ramanathan, R. K., Weiss, G. J., Chadha, M., Oey, A., Ding, H. T., Culp, P. A., Keller, S. F., Zhao, V. Y., Tsao, L. C., Singhal, A., Holen, K. D. & Von Hoff, D., Jan 1 2018, In : Molecular Cancer Therapeutics. 17, 1, p. 215-221 7 p.

Research output: Contribution to journalArticle

4 Scopus citations
2017

18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer

Korn, R. L., Von Hoff, D. D., Borad, M. J., Renschler, M. F., McGovern, D., Curtis Bay, R. & Ramanathan, R. K., Aug 3 2017, In : Cancer Imaging. 17, 1, 23.

Research output: Contribution to journalArticle

4 Scopus citations

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients

Ramanathan, R. K., Weiss, G. J., Posner, R. G., Rajeshkumar, N. V., Jameson, G., Aziz, M., Hoering, A., Bolejack, V., Maitra, A., Fulk, M., Stites, E. C., Hlavacek, W. S., Gatalica, Z., Xiu, J., Hidalgo, M., Von Hoff, D. D. & Barrett, M., Dec 1 2017, In : Journal of Gastrointestinal Oncology. 8, 6, p. 925-935 11 p.

Research output: Contribution to journalArticle

Clinical study of genomic drivers in pancreatic ductal adenocarcinoma

Barrett, M., Deiotte, R., Lenkiewicz, E., Malasi, S., Holley, T., Evers, L., Posner, R. G., Jones, T., Han, H., Sausen, M., Velculescu, V. E., Drebin, J., O'Dwyer, P., Jameson, G., Ramanathan, R. K. & Von Hoff, D. D., Aug 8 2017, In : British Journal of Cancer. 117, 4, p. 572-582 11 p.

Research output: Contribution to journalArticle

11 Scopus citations

Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: A pilot study

Ramanathan, R. K., Korn, R. L., Raghunand, N., Sachdev, J. C., Newbold, R. G., Jameson, G., Fetterly, G. J., Prey, J., Klinz, S. G., Kim, J., Cain, J., Hendriks, B. S., Drummond, D. C., Bayever, E. & Fitzgerald, J. B., Jul 15 2017, In : Clinical Cancer Research. 23, 14, p. 3638-3648 11 p.

Research output: Contribution to journalArticle

56 Scopus citations

Development of new pharmaceutical therapies for pancreatic adenocarcinoma

Ramanathan, R. K., Nov 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 11, p. 7-10 4 p.

Research output: Contribution to journalArticle

Molecular modeling and functional analysis of exome sequencing-derived variants of unknown significance identify a novel, constitutively active FGFR2 mutant in cholangiocarcinoma

Egan, J. B., Marks, D. L., Hogenson, T. L., Vrabel, A. M., Sigafoos, A. N., Tolosa, E. J., Carr, R. M., Safgren, S. L., Hesles, E. E., Almada, L. L., Romecin-Duran, P. A., Iguchi, E., Ala'Aldeen, A., Kocher, J. P. A., Oliver, G. R., Prodduturi, N., Mead, D. W., Hossain, A., Huneke, N. E., Tagtow, C. M. & 43 others, Ailawadhi, S., Ansell, S. M., Banck, M. S., Bryce, A. H., Carballido, E. M., Chanan-Khan, A. A., Curtis, K. K., Resnik, E., Gawryletz, C. D., Go, R. S., Halfdanarson, T. R., Ho, T. H., Joseph, R. W., Kapoor, P., Mansfield, A. S., Meurice, N., Rao, A. A. N., Nowakowski, G. S., Pardanani, A., Parikh, S. A., Cheville, J. C., Feldman, A. L., Ramanathan, R. K., Robinson, S. I., Tibes, R., Finnes, H. D., McCormick, J. B., McWilliams, R. R., Jatoi, A., Patnaik, M. M., Silva, A. C., Wieben, E. D., McAllister, T. M., Rumilla, K. M., Kerr, S. E., Lazaridis, K. N., Farrugia, G., Keith Stewart, A., Clark, K. J., Kennedy, E. J., Klee, E. W., Borad, M. J. & Fernandez-Zapico, M. E., Jan 1 2017, In : JCO Precision Oncology. 2017, 1, p. 1-13 13 p.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers

de Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., Henshaw, J. W., Herriott, A., Patterson, M., Curtin, N. J., Byers, L. A. & Wainberg, Z. A., Jan 1 2017, In : Cancer discovery. 7, 6, p. 620-629 10 p.

Research output: Contribution to journalArticle

142 Scopus citations

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors

Weiss, G. J., Jameson, G., von Hoff, D. D., Valsasina, B., Davite, C., Di Giulio, C., Fiorentini, F., Alzani, R., Carpinelli, P., Di Sanzo, A., Galvani, A., Isacchi, A. & Ramanathan, R. K., Jul 20 2017, (Accepted/In press) In : Investigational New Drugs. p. 1-11 11 p.

Research output: Contribution to journalArticle

10 Scopus citations

Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors

Juric, D., Krop, I., Ramanathan, R. K., Wilson, T. R., Ware, J. A., Sanabria Bohorquez, S. M., Savage, H. M., Sampath, D., Salphati, L., Lin, R. S., Jin, H., Parmar, H., Hsu, J. Y., Von Hoff, D. D. & Baselga, J., Jul 2017, In : Cancer discovery. 7, 7, p. 704-715 12 p.

Research output: Contribution to journalArticle

61 Scopus citations

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis

Borazanci, E., Millis, S. Z., Kimbrough, J., Doll, N., von Hoff, D. & Ramanathan, R. K., 2017, In : Journal of Gastrointestinal Oncology. 8, 1, p. 164-172 9 p.

Research output: Contribution to journalArticle

19 Scopus citations

Recent advances in the treatment of pancreatic adenocarcinoma

Braiteh, F., Ramanathan, R. K. & Bekaii-Saab, T., Nov 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 11, p. 1-2 2 p.

Research output: Contribution to journalArticle

Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer

Goldstein, D., Von Hoff, D., Chiorean, E., Reni, M., Tabernero, J., Ramanathan, R., Wilkerson, J., Botteman, M., Aly, A., Margunato-Debay, S., Lu, B., Louis, C., Renschler, M., McGovern, D. & Lee, C., Jun 1 2017, In : Annals of oncology : official journal of the European Society for Medical Oncology. 28, p. iii142-iii144

Research output: Contribution to journalArticle

Open Access
9 Scopus citations

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis

Sonbol, M. B., Firwana, B., Wang, Z., Almader-Douglas, D., Borad, M. J., Makhoul, I., Ramanathan, R. K., Ahn, D. & Bekaii-Saab, T., Dec 1 2017, In : Cancer. 123, 23, p. 4680-4686 7 p.

Research output: Contribution to journalArticle

12 Scopus citations

Tumor reduction in primary andmetastatic pancreatic cancer lesions with nab-paclitaxel and gemcitabine: An exploratory analysis from a phase 3 study

Kunzmann, V., Ramanathan, R. K., Goldstein, D., Liu, H., Ferrara, S., Lu, B., Renschler, M. F. & Von Hoff, D. D., 2017, In : Pancreas. 46, 2, p. 203-208 6 p.

Research output: Contribution to journalArticle

13 Scopus citations
2016
1 Scopus citations

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V., Ramanathan, R. K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B. & Ko, A., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 654-660 7 p., mdw006.

Research output: Contribution to journalArticle

44 Scopus citations

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A cohort study

Kasi, P. M., Kotani, D., Cecchini, M., Shitara, K., Ohtsu, A., Ramanathan, R. K., Hochster, H. S., Grothey, A. F. & Yoshino, T., Jul 13 2016, In : BMC Cancer. 16, 1, 467.

Research output: Contribution to journalArticle

35 Scopus citations

Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers

Borad, M. J., Egan, J. B., Condjella, R. M., Liang, W. S., Fonseca, R., Ritacca, N. R., McCullough, A. E., Barrett, M., Hunt, K. S., Champion, M. D., Patel, M. D., Young, S. W., Silva, A. C., Ho, T. H., Halfdanarson, T. R., Mc Williams, R. R., Lazaridis, K. N., Ramanathan, R. K., Baker, A., Aldrich, J. & 17 others, Kurdoglu, A., Izatt, T., Christoforides, A., Cherni, I., Nasser, S., Reiman, R., Cuyugan, L., McDonald, J., Adkins, J., Mastrian, S. D., Valdez, R., Jaroszewski, D. E., Von Hoff, D. D., Craig, D. W., Stewart, A. K., Carpten, J. D. & Bryce, A. H., 2016, In : Scientific Reports. 6, 1, 25.

Research output: Contribution to journalArticle

11 Scopus citations

Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)

Goldstein, D., Von Hoff, D. D., Moore, M., Greeno, E., Tortora, G., Ramanathan, R. K., Macarulla, T., Liu, H., Pilot, R., Ferrara, S. & Lu, B., Jan 1 2016, In : European Journal of Cancer. 52, p. 85-91 7 p.

Research output: Contribution to journalArticle

17 Scopus citations

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: Phase III MPACT trial

Scheithauer, W., Ramanathan, R. K., Moore, M., Macarulla, T., Goldstein, D., Hammel, P., Kunzmann, V., Liu, H., McGovern, D., Romano, A. & Von Hoff, D. D., Jun 1 2016, In : Journal of Gastrointestinal Oncology. 7, 3, p. 469-478 10 p.

Research output: Contribution to journalArticle

22 Scopus citations

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

Patnaik, A., Appleman, L. J., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Weiss, G. J., Sachdev, J. C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J. M., Lotze, M. T., Toledo, F. G. S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I. & 1 others, Ramanathan, R. K., Jan 1 2016, In : Annals of Oncology. 27, 10, p. 1928-1940 13 p.

Research output: Contribution to journalArticle

Open Access
81 Scopus citations

Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors

Von Hoff, D. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., Lorusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Parsons, D. M., Zale, S. E., Summa, J. M., Youssoufian, H. & Sachdev, J. C., Jul 1 2016, In : Clinical Cancer Research. 22, 13, p. 3157-3163 7 p.

Research output: Contribution to journalArticle

90 Scopus citations

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

Ramanathan, R. K., Goldstein, D., Korn, R. L., Arena, F., Moore, M., Siena, S., Teixeira, L., Tabernero, J., Van Laethem, J. L., Liu, H., McGovern, D., Lu, B. & Von Hoff, D. D., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 648-653 6 p., mdw020.

Research output: Contribution to journalArticle

20 Scopus citations

Safety, pharmacokinetics, and pharmacodynamics of a humanized anti-semaphorin 4D antibody, in a first-in-human study of patients with advanced solid tumors

Patnaik, A., Weiss, G. J., Leonard, J. E., Rasco, D., Sachdev, J. C., Fisher, T. L., Winter, L. A., Reilly, C., Parker, R. B., Mutz, D., Blaydorn, L., Tolcher, A. W., Zauderer, M. & Ramanathan, R. K., Feb 15 2016, In : Clinical Cancer Research. 22, 4, p. 827-836 10 p.

Research output: Contribution to journalArticle

30 Scopus citations

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: A first-in-human, open-label, dose-escalation phase i study with expansion cohort

Burris, H. A., Bakewell, S., Bendell, J. C., Infante, J., Jones, S. F., Spigel, D. R., Weiss, G. J., Ramanathan, R. K., Ogden, A. & Von Hoff, D., Dec 1 2016, In : ESMO Open. 1, 6, e000154.

Research output: Contribution to journalArticle

37 Scopus citations
2015

90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

Picozzi, V. J., Ramanathan, R. K., Lowery, M. A., Ocean, A. J., Mitchel, E. P., O'neil, B. H., Guarino, M. J., Conkling, P. R., Cohen, S. J., Bahary, N., Frank, R. C., Dragovich, T., Bridges, B. B., Braiteh, F. S., Starodub, A. N., Lee, F. C., Gribbin, T. E., Richards, D. A., Lee, M., Korn, R. L. & 11 others, Pandit-Taskar, N., Goldsmith, S. J., Intenzo, C. M., Sheikh, A., Manzone, T. C., Horne, H., Sharkey, R. M., Wegener, W. A., O'reilly, E. M., Goldenberg, D. M. & Von Hoff, D. D., Jun 7 2015, In : European Journal of Cancer. 51, 14, p. 1857-1864 8 p., 9522.

Research output: Contribution to journalArticle

7 Scopus citations

A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)

Infante, J. R., Ramanathan, R. K., George, D., Tan, E., Quinlan, M., Liu, A., Scott, J. W. & Sharma, S., Apr 2015, In : Cancer chemotherapy and pharmacology. 75, 4, p. 729-737 9 p.

Research output: Contribution to journalArticle

4 Scopus citations

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer

Barrett, M., Anderson, K. S., Lenkiewicz, E., Andreozzi, M., Cunliffe, H. E., Klassen, C. L., Dueck, A., McCullough, A. E., Reddy, S. K., Ramanathan, R. K., Northfelt, D. W. & Pockaj, B. A., 2015, In : Oncotarget. 6, 28, p. 26483-26493 11 p.

Research output: Contribution to journalArticle

67 Scopus citations

Late-stage cancer patients remain highly responsive to immune activation by the selective TLR8 agonist motolimod (VTX-2337)

Dietsch, G. N., Randall, T. D., Gottardo, R., Northfelt, D. W., Ramanathan, R. K., Cohen, P. A., Manjarrez, K. L., Newkirk, M., Bryan, J. K. & Hershberg, R. M., Dec 15 2015, In : Clinical Cancer Research. 21, 24, p. 5445-5452 8 p.

Research output: Contribution to journalArticle

16 Scopus citations

Metastatic fibrolamellar hepatocellular carcinoma to the pancreas

Villa, N. A., Pannala, R., Faigel, D. O., Haakinson, D. J., Katariya, N., Ramanathan, R. K., Jaroszewski, D., Lidner, T. K. & Byrne, T., May 1 2015, In : Case Reports in Gastroenterology. 9, p. 266-271 6 p.

Research output: Contribution to journalArticle

2 Scopus citations

Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)

Ramanathan, R. K., McDonough, S. L., Kennecke, H. F., Iqbal, S., Baranda, J. C., Seery, T. E., Lim, H. J., Hezel, A. F., Vaccaro, G. M. & Blanke, C. D., Jul 1 2015, In : Cancer. 121, 13, p. 2193-2197 5 p.

Research output: Contribution to journalArticle

44 Scopus citations

Prognostic factorsofsurvival inarandomizedphaseIIItrial (MPACT)of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Tabernero, J., Gabrielachiorean, E., Infante, J. R., Hingorani, S. R., Ganju, V., Weekes, C., Scheithauer, W., Ramanathan, R. K., Goldstein, D., Penenberg, D. N., Romano, A., Ferrara, S. & Von Hoff, D. D., Jan 12 2015, In : Oncologist. 20, 2, p. 143-150 8 p.

Research output: Contribution to journalArticle

69 Scopus citations

Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer

Song, G., Tarrant, T. K., White, T. F., Barrow, D. A., Santos, C. M., Timoshchenko, R. G., Hanna, S. K., Ramanathan, R. K., Lee, C. R., Bae-Jump, V. L., Gehrig, P. A. & Zamboni, W. C., Oct 1 2015, In : Nanomedicine: Nanotechnology, Biology, and Medicine. 11, 7, p. 1797-1807 11 p.

Research output: Contribution to journalArticle

11 Scopus citations